Valion Bio, Inc. Common Stock (NASDAQ:VBIO) vs. Arcus Biosciences (NYSE:RCUS) Head-To-Head Comparison
by Sarita Garza · The Markets DailyValion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) and Arcus Biosciences (NYSE:RCUS – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.
Volatility and Risk
Valion Bio, Inc. Common Stock has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Valion Bio, Inc. Common Stock and Arcus Biosciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Valion Bio, Inc. Common Stock | 1 | 0 | 0 | 0 | 1.00 |
| Arcus Biosciences | 1 | 3 | 12 | 0 | 2.69 |
Arcus Biosciences has a consensus price target of $38.55, indicating a potential upside of 74.69%. Given Arcus Biosciences’ stronger consensus rating and higher probable upside, analysts plainly believe Arcus Biosciences is more favorable than Valion Bio, Inc. Common Stock.
Profitability
This table compares Valion Bio, Inc. Common Stock and Arcus Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Valion Bio, Inc. Common Stock | N/A | -193.17% | -67.10% |
| Arcus Biosciences | -393.16% | -89.54% | -45.61% |
Valuation and Earnings
This table compares Valion Bio, Inc. Common Stock and Arcus Biosciences”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Valion Bio, Inc. Common Stock | $780,000.00 | 1.33 | -$8.88 million | ($159.25) | -0.01 |
| Arcus Biosciences | $247.00 million | 11.37 | -$353.00 million | ($3.90) | -5.66 |
Valion Bio, Inc. Common Stock has higher earnings, but lower revenue than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 2.5% of Valion Bio, Inc. Common Stock shares are held by insiders. Comparatively, 7.6% of Arcus Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Arcus Biosciences beats Valion Bio, Inc. Common Stock on 10 of the 14 factors compared between the two stocks.
About Valion Bio, Inc. Common Stock
Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.
About Arcus Biosciences
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.